Opioid API firm Noramco moves into cannabinoids

By Gareth Macdonald

- Last updated on GMT

iStock/andykatz
iStock/andykatz

Related tags Cannabis

Noramco has added cannabinoids to its portfolio of opioid APIs.

The US opioid-based active pharmaceutical ingredient (API) announced its intention to reshape its businesses this week, explaining that it has started supplying cannabinoids in response to growing drug industry demand.

The former J&J unit told us “after recently adding the full line of mixed amphetamines to our product list Noramco is adding Cannabidiol for Clinical and Pharmaceutical use to our product portfolio​. “

Noramco said it had leveraged its experience making dronabinol - a synthetic form of cannabis used to treat loss of appetite that causes weight loss in AIDS patients – to develop the new products and expand its intellectual property portfolio (IP).

The firm was recently awarded two US patent - 2017/0008868 and 2017/0008869 – which cover the production of cannabidiol and delta-9-Tetrahydrocannabinol. 

Services business

Noramco also provided details on the services business it has set up, telling us it will run in parallel to its ingredients operation.

The firm said: “Building on a foundation of extensive API product knowledge Noramco is developing specific excipient and API packages to enable customers to reduce their time to market and ensure that their formulations perform well on stability.”

Geographic expansion

Noramco currently supplies controlled substance APIs to customers serving 25 markets, including Latin America and China.

The firm told us it plans to build on this, explaining that: “To further accelerate emerging market penetration Noramco is planning to increase dossier registration even further and evaluation a method to offer a direct presence and controlled substance distribution capabilities.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...